Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, rec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Boone NW, van Leeuwen RWF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/43edcb1ca8cf4cafa08fd527b225072a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43edcb1ca8cf4cafa08fd527b225072a
record_format	dspace
spelling	oai:doaj.org-article:43edcb1ca8cf4cafa08fd527b225072a2021-12-02T04:54:25ZTissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?1177-54671177-5483https://doaj.org/article/43edcb1ca8cf4cafa08fd527b225072a2012-01-01T00:00:00Zhttp://www.dovepress.com/tissue-plasminogen-activator-tpa-in-the-management-of-predominantly-he-a9097https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, received a request for the aseptic preparation of an alteplase syringe solution for subretinal administration. Looking for dose rationale, our ophthalmology doctor came up with a concentration based on an article published by Arias and colleagues in Clinical Ophthalmology in 2010.Boone NWvan Leeuwen RWFDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 145-146 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Boone NW van Leeuwen RWF Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
description	Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, received a request for the aseptic preparation of an alteplase syringe solution for subretinal administration. Looking for dose rationale, our ophthalmology doctor came up with a concentration based on an article published by Arias and colleagues in Clinical Ophthalmology in 2010.
format	article
author	Boone NW van Leeuwen RWF
author_facet	Boone NW van Leeuwen RWF
author_sort	Boone NW
title	Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
title_short	Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
title_full	Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
title_fullStr	Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
title_full_unstemmed	Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
title_sort	tissue plasminogen activator (tpa) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/43edcb1ca8cf4cafa08fd527b225072a
work_keys_str_mv	AT boonenw tissueplasminogenactivatortpainthemanagementofpredominantlyhemorrhagicagerelatedmaculardegenerationmilligrammilliliterormicrogrammilliliter AT vanleeuwenrwf tissueplasminogenactivatortpainthemanagementofpredominantlyhemorrhagicagerelatedmaculardegenerationmilligrammilliliterormicrogrammilliliter
_version_	1718401001273163776

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

Ejemplares similares